See more : Traccom Inc. (TRCC) Income Statement Analysis – Financial Results
Complete financial analysis of Eisai Co., Ltd. (ESAIY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eisai Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Secure Energy Services Inc. (SES.TO) Income Statement Analysis – Financial Results
- Marvel Discovery Corp. (MARVF) Income Statement Analysis – Financial Results
- Reach Subsea ASA (REACH.OL) Income Statement Analysis – Financial Results
- Indivior PLC (INDV) Income Statement Analysis – Financial Results
- GenusPlus Group Limited (GNSPF) Income Statement Analysis – Financial Results
Eisai Co., Ltd. (ESAIY)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.eisai.co.jp
About Eisai Co., Ltd.
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 741.75B | 744.40B | 756.23B | 645.94B | 695.62B | 642.83B | 600.05B | 539.10B | 547.92B | 548.47B | 600.35B | 573.68B | 647.93B | 768.93B | 803.14B | 781.71B | 734.42B | 674.18B | 601.26B | 533.14B | 500.13B | 466.61B | 431.75B | 361.71B | 302.47B |
| Cost of Revenue | 155.33B | 177.84B | 174.83B | 161.31B | 175.69B | 184.49B | 201.25B | 195.91B | 194.46B | 193.60B | 188.16B | 174.11B | 173.35B | 167.78B | 160.73B | 152.41B | 118.94B | 109.37B | 104.51B | 98.61B | 97.18B | 102.47B | 101.57B | 98.60B | 91.68B |
| Gross Profit | 586.42B | 566.57B | 581.40B | 484.63B | 519.93B | 458.34B | 398.80B | 343.19B | 353.46B | 354.87B | 412.20B | 399.57B | 474.57B | 601.15B | 642.41B | 629.29B | 615.48B | 564.81B | 496.75B | 434.53B | 402.95B | 364.15B | 330.18B | 263.11B | 210.79B |
| Gross Profit Ratio | 79.06% | 76.11% | 76.88% | 75.03% | 74.74% | 71.30% | 66.46% | 63.66% | 64.51% | 64.70% | 68.66% | 69.65% | 73.24% | 78.18% | 79.99% | 80.50% | 83.81% | 83.78% | 82.62% | 81.50% | 80.57% | 78.04% | 76.47% | 72.74% | 69.69% |
| Research & Development | 169.02B | 173.00B | 171.74B | 150.30B | 140.12B | 144.84B | 139.58B | 112.48B | 122.31B | 131.91B | 130.54B | 120.38B | 0.00 | 0.00 | 0.00 | 0.00 | 225.43B | 108.30B | 93.25B | 78.33B | 69.02B | 59.70B | 55.04B | 49.61B | 46.70B |
| General & Administrative | 374.42B | 358.29B | 366.43B | 281.40B | 256.30B | 228.21B | 183.86B | 179.68B | 192.82B | 194.55B | 152.32B | 139.85B | 0.00 | 0.00 | 0.00 | 0.00 | 372.30B | 351.25B | 307.80B | 269.39B | 250.87B | 228.44B | 202.46B | 154.66B | 127.05B |
| Selling & Marketing | -10.34B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 58.22B | 68.88B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 364.08B | 358.29B | 366.43B | 281.40B | 256.30B | 228.21B | 183.86B | 179.68B | 192.82B | 194.55B | 210.54B | 208.73B | 0.00 | 0.00 | 0.00 | 0.00 | 372.30B | 351.25B | 307.80B | 269.39B | 250.87B | 228.44B | 202.46B | 154.66B | 127.05B |
| Other Expenses | 0.00 | 0.00 | -10.52B | 1.17B | -1.99B | -866.00M | -1.85B | -8.03B | -13.60B | 80.00M | -109.00M | -138.00M | 924.00M | 924.00M | 417.00M | -9.00M | 616.00M | 873.00M | 459.00M | 555.00M | -43.00M | 1.00M | 864.00M | -130.00M | -96.00M |
| Operating Expenses | 532.79B | 526.53B | 527.65B | 432.87B | 394.43B | 372.19B | 321.59B | 284.13B | 301.53B | 326.53B | 341.09B | 329.10B | 378.82B | 488.03B | 556.00B | 537.48B | 597.73B | 459.55B | 401.04B | 347.72B | 319.88B | 288.15B | 257.49B | 204.14B | 173.66B |
| Cost & Expenses | 688.12B | 704.36B | 702.48B | 594.18B | 570.12B | 556.68B | 522.84B | 480.03B | 495.99B | 520.13B | 529.25B | 503.21B | 552.17B | 655.81B | 716.73B | 689.90B | 716.67B | 568.91B | 505.55B | 446.33B | 417.06B | 390.62B | 359.06B | 302.75B | 265.34B |
| Interest Income | 10.80B | 7.24B | 2.40B | 2.15B | 4.02B | 4.86B | 2.56B | 1.85B | 2.02B | 2.43B | 963.00M | 1.12B | 815.00M | 997.00M | 1.25B | 3.17B | 5.33B | 5.12B | 3.35B | 1.70B | 1.34B | 1.47B | 2.78B | 3.19B | 0.00 |
| Interest Expense | 2.39B | 2.27B | 1.69B | 1.36B | 1.46B | 1.56B | 2.97B | 3.24B | 3.49B | 4.89B | 5.55B | 6.69B | 6.89B | 7.42B | 7.66B | 7.63B | 762.00M | 65.00M | 79.00M | 52.00M | 28.00M | 56.00M | 296.00M | 687.00M | 1.13B |
| Depreciation & Amortization | 39.40B | 39.98B | 38.40B | 36.30B | 33.70B | 26.84B | 26.18B | 26.48B | 34.06B | 38.94B | 48.52B | 51.09B | 48.69B | 51.26B | 57.37B | 58.63B | 34.40B | 26.80B | 24.99B | 22.45B | 18.49B | 15.33B | 15.33B | 15.00B | 15.14B |
| EBITDA | 103.11B | 87.26B | 94.55B | 90.05B | 162.94B | 117.75B | 105.81B | 86.93B | 87.99B | 69.56B | 93.36B | 129.21B | 150.23B | 161.25B | 139.31B | 136.75B | 52.81B | 137.20B | 121.15B | 110.06B | 101.90B | 87.85B | 91.74B | 58.53B | 41.81B |
| EBITDA Ratio | 13.90% | 11.72% | 12.50% | 13.97% | 23.46% | 18.33% | 17.66% | 16.21% | 16.06% | 12.71% | 19.86% | 21.84% | 22.48% | 21.31% | 18.02% | 19.04% | 7.35% | 20.37% | 20.80% | 20.93% | 20.37% | 18.05% | 21.25% | 15.70% | 13.82% |
| Operating Income | 53.41B | 40.04B | 53.75B | 51.77B | 125.50B | 86.15B | 77.21B | 59.06B | 51.94B | 28.34B | 71.11B | 70.46B | 95.75B | 113.12B | 86.41B | 91.81B | 17.75B | 105.26B | 95.70B | 86.81B | 83.06B | 75.86B | 72.69B | 58.97B | 37.13B |
| Operating Income Ratio | 7.20% | 5.38% | 7.11% | 8.01% | 18.04% | 13.40% | 12.87% | 10.96% | 9.48% | 5.17% | 11.84% | 12.28% | 14.78% | 14.71% | 10.76% | 11.74% | 2.42% | 15.61% | 15.92% | 16.28% | 16.61% | 16.26% | 16.84% | 16.30% | 12.28% |
| Total Other Income/Expenses | 8.42B | 4.97B | 708.00M | -668.00M | 2.56B | 3.30B | -409.00M | -1.40B | -1.46B | -2.46B | -4.10B | 966.00M | -1.10B | -10.55B | -12.13B | -21.32B | -96.00M | 5.07B | 378.00M | 845.00M | -539.00M | -6.04B | -9.93B | -16.13B | -11.60B |
| Income Before Tax | 61.82B | 45.01B | 54.46B | 52.55B | 128.06B | 89.45B | 76.80B | 57.67B | 50.47B | 25.88B | 58.21B | 71.43B | 94.65B | 102.57B | 74.28B | 70.48B | 17.65B | 110.33B | 96.08B | 87.65B | 82.52B | 69.83B | 62.75B | 42.84B | 25.54B |
| Income Before Tax Ratio | 8.33% | 6.05% | 7.20% | 8.14% | 18.41% | 13.92% | 12.80% | 10.70% | 9.21% | 4.72% | 9.70% | 12.45% | 14.61% | 13.34% | 9.25% | 9.02% | 2.40% | 16.37% | 15.98% | 16.44% | 16.50% | 14.96% | 14.53% | 11.84% | 8.44% |
| Income Tax Expense | 18.04B | -11.82B | 8.74B | 10.07B | 5.60B | 22.97B | 22.38B | 15.42B | -4.57B | -17.58B | 25.03B | 22.88B | 35.71B | 34.79B | 33.41B | 22.13B | 37.19B | 39.20B | 32.23B | 31.80B | 32.93B | -28.61B | 26.10B | 19.63B | -14.20B |
| Net Income | 42.41B | 55.43B | 47.95B | 41.94B | 121.77B | 63.39B | 51.85B | 39.36B | 54.93B | 43.25B | 32.96B | 48.28B | 58.51B | 67.39B | 40.34B | 47.68B | -17.01B | 70.61B | 63.41B | 55.51B | 50.15B | 41.03B | 36.80B | 23.32B | 11.28B |
| Net Income Ratio | 5.72% | 7.45% | 6.34% | 6.49% | 17.50% | 9.86% | 8.64% | 7.30% | 10.03% | 7.89% | 5.49% | 8.42% | 9.03% | 8.76% | 5.02% | 6.10% | -2.32% | 10.47% | 10.55% | 10.41% | 10.03% | 8.79% | 8.52% | 6.45% | 3.73% |
| EPS | 147.86 | 193.31 | 167.27 | 146.95 | 425.01 | 221.02 | 724.71 | 550.52 | 768.92 | 606.28 | 536.52 | 677.52 | 821.32 | 946.08 | 566.32 | 669.40 | -59.32 | 991.40 | 887.24 | 776.88 | 697.04 | 553.36 | 500.64 | 311.51 | 152.13 |
| EPS Diluted | 147.86 | 193.30 | 167.25 | 146.90 | 424.80 | 221.02 | 723.89 | 549.64 | 767.04 | 605.48 | 536.04 | 677.24 | 821.24 | 946.04 | 566.24 | 669.20 | -59.32 | 991.40 | 887.24 | 776.88 | 697.04 | 553.36 | 500.64 | 311.51 | 152.13 |
| Weighted Avg Shares Out | 286.80M | 286.76M | 286.69M | 286.62M | 286.51M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M |
| Weighted Avg Shares Out (Dil) | 286.80M | 286.76M | 286.73M | 286.71M | 286.65M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M |
C₂N Diagnostics, LLC Announces Investment From Eisai Inc.
ST. LOUIS--(BUSINESS WIRE)-- #Alzheimers--C₂N Diagnostics, LLC, a leader in advanced brain health diagnostics, and Eisai Inc., a “human health care company,” have announced Eisai has made an investment of up to 15 million USD in C₂N. C₂N executives say the...
3 Millionaire-Maker Stocks to Buy While the Gettin' Is Good
In order to turn $50,000 into $1 million by investing, you have to find stocks that the Street is underestimating. Of course, to achieve that tremendous feat, investors also have to choose companies that can grow tremendously by exploiting strong...
Eisai Co Ltd (ESALF) Q3 2023 Earnings Call Transcript
Eisai Co Ltd (ESALF) Q3 2023 Earnings Call Transcript
Exclusive: Eisai expects 1,500 Alzheimer's patients in China launch, sees ‘huge' growth
Japan's Eisai aims to roll out its groundbreaking Alzheimer's drug Leqembi to 1,500 people in China later this year, but expects growth to accelerate significantly in 2025 as diagnosis methods change, a company spokesperson told Reuters.
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
Some of the worst and most deadly diseases affect our brains. In multiple sclerosis, the immune system “causes communication problems between your brain and the rest of your body,” preventing some victims from walking.
China approves Alzheimer's treatment Leqembi by Eisai and Biogen
Eisai and Biogen said on Tuesday that their Alzheimer's treatment Leqembi had won approval in China, the third country after the United States and Japan.
ANGLE teams up with Eisai for breast cancer pilot study
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of a unique diagnostic focused on circulating tumour cells (CTCs) associated with cancer, has landed a contract with Eisai Inc, the Japanese pharma group, worth US$250,000. The pilot study will utilise ANGLE's Portrait HER2...
3 Aging Population Stocks to Profit from the Boomer Generation
As the Baby Boomers age, the number of elderly Americans has risen quickly. Specifically, the number of those 65 and older in the U.S. jumped 38.6% between 2010 and 2020 to 55.8 million.
Eisai to launch Alzheimer's drug Leqembi in Japan on Dec 20
Eisai said on Wednesday its Alzheimer's drug Leqembi will launch in Japan on Dec. 20 following its inclusion on the National Health Insurance price list.
Merck-Eisai uterine cancer drug combination fails first-line treatment study
Merck & Co Inc (NYSE:MRK) and Eisai announced Friday that their therapeutic combination targeting endometrial cancer as a first-line treatment failed to meaningfully slow the progression of the disease or improve overall survival during a late-stage trial. The Phase 3 LEAP-001...
Source: https://incomestatements.info
Category: Stock Reports